Healthy subjects vs. patients [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2011-11-28 13:56 (4532 d 01:58 ago) – Posting: # 7741
Views: 5,604

Dear VM!

❝ […] kindly explain me can i enroll healthy subjects for biosimilars BA/BE study ?


In the EU biosimilars are solely registered centrally at EMA. This process includes submission of protocols and generally scientific advisory meetings… You are aware that you need to perform phase III studies in the patient population to demonstrate safety/efficacy? When it comes to BE, healthy volunteers should be OK – providing safety/efficacy are not an issue. If possible include PD endpoints in the PK studies. See also the recent concept paper.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,653 registered users;
116 visitors (0 registered, 116 guests [including 4 identified bots]).
Forum time: 16:55 CEST (Europe/Vienna)

Never never never never use Excel.
Not even for calculation of arithmetic means.    Martin Wolfsegger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5